Innovative formulations based on deep eutectic solvents for the treatment of cutaneous leishmaniasis. – ParasiDES
Development of a new topical form for the treatment of cutaneous leishmaniasis
The objective of the ParasiDES project is to develop a new topical treatment of cutaneous leishmaniasis that is simple, effective and inexpensive.
An innovative project
They are numerous studies concerning the topical delivery of antiparasitic drug for the treatment of cutaneous leishmaniasis. However, these formulations are not always effective, are expensive and complex or use aqueous solvents, that can be detrimental to stability in particular. So there is a need to develop simple and inexpensive formulations suitable for dermal administration and effective for the treatment of CL. In our project, we wish to formulate composed of DES and an antiparasitic drug. These kind of solvents could improve the solubility of low-aqueous-soluble or volatile molecules. In addition, these formulations are prepared without water, which allows us to consider a better stability especially a better stability microbiological. Moreover, DES are very modular systems, and their textures and viscosities can be adjusted for the desired application and their compositions can be tuned in order to promote the penetration of active ingredients and improve the appearance of the skin.
The project implements six tasks:
Task 1 DES preparation
Task 2 Drug solubilization
Task 3 Formulation characterization
Task 4 Evaluation of therapeutic efficacy
Task 5 Evaluation of DES using an ex vivo skin model
Task 6 Evaluation of DES using a 3D keratinocyte model
The project implements both different and complementary techniques (physical and analytical chemistry, biology, animal experimentation) necessary for the realization of the project.
The first results of ParasiDES project are:
- a better understanding of the toxicological behavior of DES on an in-vitro 3D model of skin
- an in-vivo evaluation of the safety of DES on an animal model.
to be develop
One publication (10/01/2022)
New generation of supramolecular mixtures: Characterization and solubilization studies, T. El Achkar, L. Moura, T. Moufawad, S. Ruellan, S. Panda, S. Longuemart, F.-X. Legrand, M. Costa Gomes, D. Landy, H. Greige-Gerges, S. Fourmentin, International Journal of Pharmaceutics, 2020, 584, 119443 (https://doi.org/10.1016/j.ijpharm.2020.119443)
One book chapter (10/01/2022)
Deep Eutectic Solvents for Innovative Pharmaceutical Formulations, Canh-Hung Nguyen, Luc Augis, Sophie Fourmentin, Gillian Barratt, François-Xavier Legrand, Deep Eutectic Solvents for Medicine, Gas Solubilization and Extraction of Natural Substances, 2021, 41-102 (https://doi.org/10.1007/978-3-030-53069-3_2 ; hal.archives-ouvertes.fr/hal-03282900/)
Cutaneous leishmaniases are infections whose current first-line treatment is antimony derivatives administered by painful intralesional injection. There is a need to develop topical formulations that are more comfortable for the patient but effective for delivering active molecules to the dermis. Deep eutectic solvents (DES) are mixtures of two solids that remain liquid at room temperature through the formation of a hydrogen bonding network. These systems have recently demonstrated their ability to improve the solubility and skin penetration of both lipophilic and high molecular weight molecules. Their simple and inexpensive preparation would allow the development of accessible treatments for people living in endemic areas for this disease (developing countries). Thus, we propose to develop a new topical treatment of cutaneous leishmaniasis that is simple, effective and inexpensive.
Project coordination
François-Xavier Legrand (François-Xavier LEGRAND)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partnership
IGPS François-Xavier LEGRAND
Help of the ANR 358,516 euros
Beginning and duration of the scientific project:
December 2019
- 42 Months
